Ipilimumab and Nivolumab in Combination With Immunoembolization for the Treatment of Metastatic Uveal Melanoma
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Liver metastases; Uveal melanoma
- Focus Therapeutic Use
- 01 Nov 2018 Status changed from recruiting to suspended.
- 11 May 2018 Status changed from not yet recruiting to recruiting.
- 22 Mar 2018 New trial record